Ten tumors were negative for mutations in KIT, PDGFRA, and RAS-pathway genes (BRAF, RAS isoforms, and NF1), and for all other 161 cancer-relevant genes that were included in our NGS panel. This evidence concerns the gene PDGFRA and cancer.